Scarica l'app Stockscreener
24.35
0.12%
-0.0393
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PFE Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$24.39
Aprire:
$24.44
Volume 24 ore:
18.65M
Relative Volume:
0.39
Capitalizzazione di mercato:
$138.39B
Reddito:
$63.83B
Utile/perdita netta:
$10.77B
Rapporto P/E:
12.95
EPS:
1.8799
Flusso di cassa netto:
$12.44B
1 W Prestazione:
-3.49%
1M Prestazione:
+1.92%
6M Prestazione:
+10.53%
1 anno Prestazione:
-17.90%
Intervallo 1D:
$24.33
$24.61
Intervallo di 1 settimana:
$24.21
$25.42
Portata 52W:
$20.91
$29.53
Pfizer Inc Stock (PFE) Company Profile
Nome
Pfizer Inc
Settore
Industria
Telefono
(212) 733-2323
Indirizzo
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Confronta PFE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
24.34 | 139.41B | 63.83B | 10.77B | 12.44B | 1.8799 |
|
LLY
Lilly Eli Co
|
820.04 | 728.24B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
191.54 | 459.63B | 92.15B | 25.12B | 18.18B | 10.36 |
|
ABBV
Abbvie Inc
|
226.73 | 404.77B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
130.65 | 252.16B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
84.12 | 211.56B | 63.43B | 16.42B | 14.72B | 6.4861 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-25 | Ripresa | Citigroup | Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-08-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Downgrade | Argus | Buy → Hold |
| 2024-02-23 | Iniziato | Guggenheim | Buy |
| 2024-01-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-10-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-17 | Reiterato | JP Morgan | Neutral |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-06-29 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Downgrade | UBS | Buy → Neutral |
| 2023-01-17 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-12-13 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-04-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-20 | Reiterato | Cowen | Outperform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-13 | Aggiornamento | UBS | Neutral → Buy |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-05-06 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-12-16 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Ripresa | Goldman | Neutral |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-10-12 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-16 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-27 | Aggiornamento | Standpoint Research | Hold → Buy |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-07-30 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Ripresa | Morgan Stanley | Overweight |
| 2019-02-20 | Ripresa | Citigroup | Neutral |
| 2019-01-31 | Aggiornamento | Argus | Hold → Buy |
| 2019-01-31 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Downgrade | UBS | Buy → Neutral |
| 2018-12-11 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Mostra tutto
Pfizer Inc Borsa (PFE) Ultime notizie
Press Release: Congressman Bill Huizenga Applauds Trump Administration and Pfizer's Agreement to Lower Drug Prices and Invest in U.S. - Quiver Quantitative
Pfizer CEO Says Vaccine Approvals Are Harder to Get Right Now - Bloomberg.com
Why Moderna Might Be a One-Hit Wonder - The Motley Fool
AstraZeneca joins Pfizer in most-favored nation pricing program - TechTarget
Advanced Ovarian Cancer Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Pfizer, Daiichi Sankyo, Astellas Pharma, Jiangsu HengRui, Boehringer - Barchart.com
GSK Fights Pfizer's Bid To Nix COVID-19 Vaccine Patents - Law360
Pfizer CEO Reportedly Says US Pharmaceutical Industry Should Collaborate With Chinese Counterparts - MarketScreener
Pfizer touts Tukysa in front-line breast cancer after Phase III victory - Yahoo Finance
Pfizer touts new Phase III win for Tukysa in front-line breast cancer - The Pharma Letter
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 3% Dividend Yields - Benzinga
Pfizer (PFE) CEO Advocates for Collaboration with China's Pharma Industry - GuruFocus
Pfizer (PFE) CEO Highlights China's Rapid Drug Development - GuruFocus
Pfizer CEO touts China's 'dramatic speed' in biopharma, calls for U.S. collaboration - Seeking Alpha
Day 7 of Loss Streak for Pfizer Stock with -10% Return (vs. -2.6% YTD) [10/14/2025] - Trefis
Pfizer: CN Biopharma Sector Shows Astonishing Growth; US Drug Industry Must Collaborate with CN - AASTOCKS.com
Pfizer CEO says US pharma industry needs to collaborate with China - Reuters
Lobbying Update: $30,000 of PFIZER INC. lobbying was just disclosed - Quiver Quantitative
Pfizer (PFE) Faces Continued Losses Despite Bullish Analyst Rati - GuruFocus
Is Pfizer’s Latest Drug Pricing Deal a Turning Point for 2025 Valuation? - simplywall.st
Pfizer CEO Urges US-China Collaboration In Pharma; Stock Drops For 7th Day As Traders Hold For Dividend Payout - Stocktwits
Pfizer (PFE) Receives a Buy from BMO Capital - The Globe and Mail
Pfizer Seeks Expanded Use Approval For Breast Cancer Drug - Benzinga
Pfizer's (PFE) Tukysa Achieves Key Milestone in Breast Cancer Tr - GuruFocus
Pfizer (PFE) Receives a Hold from Bernstein - The Globe and Mail
Pfizer succeeds in late-stage trial for Tukysa breast cancer drug as maintenance therapy - Seeking Alpha
Pfizer (PFE) Reports Positive Results from Key Breast Cancer Tri - GuruFocus
Pfizer Says Tukysa Combination as First-Line Maintenance Meets Main Goal in Breast Cancer Trial - MarketScreener
Tukysa combination significantly improves progression-free survival as first-line maintenance in HER2+ metastatic breast cancer in HER2CLIMB-05 trial - MarketScreener
Pfizer’s breast cancer drug shows promise in first-line treatment - Investing.com
Pfizer’s breast cancer drug shows promise in first-line treatment By Investing.com - Investing.com India
TUKYSA Combination Significantly Improves Progression-Free Survival as First-Line Maintenance in HER2+ Metastatic Breast Cancer in HER2CLIMB-05 Trial - Yahoo Finance
Day 6 of Loss Streak for Pfizer Stock with -9.6% Return (vs. -1.8% YTD) [10/13/2025] - Trefis
Pfizer’s (PFE) Pipeline and Dividend Yield Make it a Compelling Income Stock - Yahoo Finance
Trump's AstraZeneca Deal Echoes Pfizer Pact. Big Pharma's Political Headaches Are Easing. - Barron's
AZN Strikes Drug Pricing Deal With Trump, Gets 3-Year Tariff Reprieve - The Globe and Mail
Pfizer Reaches Agreement with U.S. Government to Lower Drug Costs - Contract Pharma
Lawsuits Claim Pfizer Failed to Warn of Brain Tumor Risk From Birth Control Shot - Truthout
Trump Secures Major Win as AstraZeneca Joins Pfizer in Lowering US Drug Prices - Medical Daily
Global markets live: Blackstone, Pfizer, Tesla, Stellantis, AstraZeneca… - MarketScreener
Pfizer stock rises as BMO Capital reiterates Outperform rating - Investing.com
How Pfizer Inc. (PFE) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know - Yahoo Finance
IP Group shares fly on back of Metsera & Pfizer news - BusinessCloud
Verdence Capital Advisors LLC Increases Stake in Pfizer Inc. $PFE - MarketBeat
Pfizer To Highlight Advancements In Respiratory Health And Infectious Disease Research At IDWeek 2025 - TradingView
Griffin Asset Management Inc. Grows Holdings in Pfizer Inc. $PFE - MarketBeat
Pfizer to present infectious disease data at IDWeek 2025 - Investing.com
Concurrent Investment Advisors LLC Purchases 20,663 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer to Highlight Advancements in Respiratory Health and Infectious Disease Research at IDWeek 2025 - Business Wire
Vanguard Personalized Indexing Management LLC Grows Position in Pfizer Inc. $PFE - MarketBeat
Pfizer, Inc. (PFE) Stock Analysis: Exploring the 16% Upside Potential and Robust Dividend Yield - DirectorsTalk Interviews
Pfizer Inc Azioni (PFE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.71%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):